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Objectives. This analysis sought to estimate the risk ratio for
cancer incidence and cancer-related mortality associated with the
use of calcium channel blocking agents (CCBs) in a large group of
patients with chronic coronary heart disease (CHD).
Background. Recent publications contend that the use of short-
acting CCBs may double the risk of cancer incidence and possibly
increase mortality in hypertensive patients.
Methods. Cancer incidence data were obtained for 11,575
patients screened for the Bezafibrate Infarction Prevention (BIP)
study, one-half of whom were treated at the time of screening with
CCBs, over a mean follow-up period of 2.8 years. Cause-specific
mortality was available through September 1996 (mean follow-up
5.2 years). The statistical power of detecting an odds ratio >21.5
(given the cancer incidence rate of 2.1 in the nonusers of CCBs)
was 0.91. The power declined to 0.77, 0.54 and 0.41, with declining
odds ratios of 1.4, 1.3 and 1.25, respectively.
Results. Of 246 incident cancer cases, 129 occurred among the
users (2.3%) and 117 among nonusers of CCBs (2.1%). After
adjustment for age, gender and smoking, the odds ratio estimates
for all cancers combined was 1.07 (95% confidence interval [CI]
0.83 to 1.37) for CCB users relative to nonusers. The adjusted risk
ratio for all-cause mortality for age, gender and smoking and
pertinent prognostic clinical characteristics was estimated at 0.94
(95% CI 0.85 to 1.04). The adjusted risk ratio for cancer-related
mortality was 1.03 (95% CI 0.75 to 1.41).
Conclusions. Patients with CHD treated with CCBs exhibited a
similar risk of cancer incidence and total and cancer-related
mortality compared with nonusers of CCBs. This analysis pro-
vides a certain assurance that CCB use in middle-aged and elderly
patients with CHD is not associated with a meaningful difference
in cancer incidence and related mortality.
(J Am Coll Cardiol 1998;31:804–8)
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In two recent reports, Pahor et al. (1,2) raised the possibility
that calcium channel blocking agents (CCBs) may increase the
risk of developing cancer. They presented an analysis of
participants of the Established Population of Epidemiological
Studies of the Elderly (EPESE). An increased risk of cancer
associated with the use of CCB therapy postulated by those
investigators provoked apprehension among many physicians
and patients. Because long-term safety data in patients with
coronary heart disease (CHD) are lacking for most CCBs, the
aim of the present analysis was to compare the risk of cancer
incidence and cancer-related mortality between users and
nonusers of CCBs in a large sample of patients with chronic
CHD, 70% of whom had had at least one myocardial infarc-
tion. Data were collected for patients screened for participa-
tion in the Bezafibrate Infarction Prevention (BIP) study (3).
Methods
Patients. Between February 1, 1990 and October 30, 1992,
clinical and biochemical data for .20,000 male and female
patients 45 to 74 years old with suspected CHD were recorded
in the logbooks of 18 departments of cardiology in Israel.
Patients with an established diagnosis of chronic CHD (n 5
15,502) were screened for inclusion in the BIP study, and they
comprised the population in the BIP registry. The institutional
committees on human research approved the study protocol.
The study was conducted according to the principles of the
Declaration of Helsinki, and written informed consent was
obtained for all patients.
All patients screened for the BIP study underwent a
complete medical examination and a biochemical blood test.
Detailed medical history and use of medication data were
recorded. The diagnosis of CHD was based on documented
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myocardial infarction or typical angina pectoris (within 2 years
preceding the screening) accompanied by a positive exercise
test, a positive radionuclear study or at least 60% stenosis of
one major coronary artery. The major exclusion criteria were
an acute coronary event or coronary intervention within 6
months before screening, severe congestive heart failure, can-
cer or chronic liver or renal disease. The complete list has been
published elsewhere (3).
The current analysis was restricted to patients who had
been screened but not included in the BIP study (n 5 11,575).
We linked this cohort to the National Cancer Registry and
National Death Registry, using the unique identification num-
ber of each Israeli resident. Each matched record was checked
for correct identification by a computer program that provided
a core for the certainty of match. We verified the identification
numbers of the entire cohort with the National Population
Registry. Death certificate diagnoses were coded using the
system described in the ninth edition of the International
Classification of Disease (ICD-9-CM) in which cancer is
denoted by codes 140 to 209. We classified patients according
to the underlying cause of death.
During the follow-up period, for cancer incidence, ending
December 31, 1993 (mean 34 months, range 14 to 46) 246 new
cases of cancer were identified. We excluded 420 patients with
a diagnosis of cancer dated before the screening visit from the
analysis of cancer incidence and cancer-related mortality. The
follow-up period for death ended on September 30, 1996
(mean 5.2 years, range 4.0 to 6.7). Total mortality rates for a
follow-up period of 3.2 years have been reported previously
(4). We excluded 805 patients because we could not verify their
vital status from the analysis of total mortality. The propor-
tions of CCB users among the 11,575 patients with known vital
status and the 805 for whom it was not known was 50% and
47%, respectively. The mean age was 59.8 and 60.6 years, and
78% and 74% were men in these two groups, respectively. The
frequency of previous myocardial infarction (71%) and current
smoking (11%) was equal in the two groups.
Statistical analysis. The pooled risk ratio of cancer inci-
dence over 2.8 years was calculated by the Cochran-Mantel-
Haenszel method (5). The strata used for risk ratio estimates
were three age groups (,55, 55 to 64 and .65 years), gender
and smoking (current, past or never). The odds ratio for cancer
incidence controlling for potential confounding variables was
also examined using logistic regression. The Cox proportional
hazards model (6) was used to control for potential confound-
ing baseline clinical characteristics when calculating the risk
ratio estimates and confidence intervals during the longer
follow-up available for total and cancer-related mortality.
Cumulative cancer-related mortality rates in CCB users and
nonusers, adjusted for age and smoking habits by the same
method, were plotted.
Assuming that a clinically meaningful odds ratio of cancer
incidence between users and nonusers of CCBs is $1.5, the
statistical power of detecting an odds ratio of at least this
magnitude (given the cancer incidence rate of 2.1 in the
nonusers of CCBs) over the given follow-up period was 0.91.
The statistical power declined to 0.77, 0.54 and 0.41, with
declining odds ratios of 1.4, 1.3 and 1.25, respectively.
Results
At the screening visit, 5,843 patients were treated with
either nifedipine, diltiazem or verapamil. The reference group
consisted of 5,732 patients who did not receive a CCB. The
clinical characteristics of both groups have been previously
reported (3). We found concurrent use of beta-adrenergic
blocking agents in 29% and 39% and angiotensin-converting
enzyme (ACE) inhibitors in 9% and 12% of CCB users and
nonusers, respectively. Diuretic drugs (16%) were reportedly
used with equal frequency in both groups. After exclusion of
420 patients with a diagnosis of cancer before the screening
visit, 5,611 cancer-free patients reported CCB treatment and
5,543 did not.
We analyzed a total of 246 cases of cancer in both groups
(129 cases in users, 117 in nonusers of CCBs). Table 1 shows
the most frequent cancer sites.
After stratification within age, gender and smoking, the
pooled risk ratio estimate for all cancers combined was 1.07
(95% confidence interval [CI] 0.83 to 1.37) for users relative to
nonusers of CCBs. In a similar analysis applying the logistic
regression and adjusting for exact age, gender and current and
past smoking, the estimated adjusted risk was virtually identi-
cal: 1.06 (95% CI 0.82 to 1.37). The risk ratio estimates for the
specific CCBs are shown in Table 2. Further stratification
within additional baseline characteristics, including age, gen-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BIP 5 Bezafibrate Infarction Prevention study
CCB 5 calcium channel blocking agent
CHD 5 coronary heart disease
CI 5 confidence interval
EPESE 5 Established Population of Epidemiological Studies of
the Elderly






Colon/rectum (153, 154) 17 22
Bladder (188) 15 15
Prostate (185) 13 16




Kidney (189) 7 6
Stomach (151) 6 5
Other 48 32
*Numbers in parenthesis are International Classification of Disease, Ninth
Edition Revised (ICD-9-MC) codes. Data presented are number of patients.
CCB 5 calcium channel blocking agent.
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der, past myocardial infarction, hypertension, New York Heart
Association functional class, peripheral vascular disease,
chronic obstructive pulmonary disease, diabetes mellitus and
smoking, did not change the risk ratio estimates meaningfully,
reducing it slightly to 1.00 (95% CI 0.76 to 1.32). Adding the
use of diuretic drugs, beta-blockade and ACE inhibitors in the
stratifying variables also did not change the risk ratio esti-
mates, yielding 1.04 (95% CI 0.81 to 1.34).
Overall mortality analysis revealed 840 deaths (14.4%) in
the CCB users compared with 730 in the nonusers (12.7%). On
multivariate adjustment for the differences between the
groups, the adjusted risk ratio was estimated at 0.94 (95% CI
0.85 to 1.04). Adjustment was made by the Cox proportional
hazard model by age, gender, current and past smoking,
diabetes, past myocardial infarction, angina pectoris, func-
tional class, hypertension, peripheral vascular disease and
chronic obstructive pulmonary disease, all of which were
significant predictors of all-cause mortality in these patients.
The adjusted risk ratio estimates for the specific CCBs are
shown in Table 3.
Among patients free of cancer at the screening visit, there
were 83 deaths (1.5%) due to cancer in the CCB users,
compared with 75 in the nonusers (1.4%). Figure 1 shows
similar curves for cancer-related mortality among users and
nonusers of CCBs. The risk ratio estimate for cancer mortality,
adjusted for age, gender and smoking (the only variables
closely associated with cancer mortality) was 1.03 (95% CI 0.75
to 1.41). The adjusted risk ratio estimates for specific CCBs are
shown in Table 4.
Discussion
CCBs are among the most commonly used drugs for
patients with cardiovascular disease. One-half of the patients
screened for the BIP study were treated by one of the three
short-acting CCBs approved in Israel for the treatment of
angina pectoris or hypertension. We found no increased risk
for all cancers among CCB users in relation to nonusers.
Similar findings were reported recently by Jick et al. (7), who
found no evidence of a material increase in the risk of any
cancer causally associated with use of CCBs relative to use of
beta-blockers. The risk of cancer was unrelated to the duration
of CCB use. The cancer-related mortality data over an average
period of 5.2 years in our study showed a minor mortality
difference between users and nonusers of CCBs, which could
easily be related to sampling variation. Because of a different
prevalence of clinical characteristics between the groups, an
analysis was performed to adjust statistically for characteristics
that might potentially be linked to cancer and confound the
association. This analysis is consistent with similar risks of
cancer-related mortality in CCB users and nonusers.
Figure 1. Cumulative cancer-related mortality for users and nonusers
of CCBs, adjusted for age and smoking habits.
Table 2. Risk Ratio Estimates for Cancer Associated With Calcium






CCB nonusers 5,543 117 (2.1%) 1
CCB users
Total 5,611 129 (2.3%) 1.07 (0.83–1.37)
Nifedipine 1,913 47 (2.5%) 1.12 (0.80–1.57)
Diltiazem 3,193 69 (2.2%) 1.04 (0.77–1.40)
Verapamil 336 8 (2.4%) 1.16 (0.56–2.38)
Combination 169 5 (3.0%) 1.36 (0.56–3.27)
*Patients with known cancer at screening visit were excluded. †Pooled over
strata of age, gender, and current and past smoking. CCB 5 calcium channel
blocking agent; CI 5 confidence interval; Pts 5 patients; RR 5 relative risk.
Table 3. Adjusted Relative Risk Estimates for Total Mortality






CCB nonusers 5,732 730 (12.7%) 1
CCB users
Total 5,843 840 (14.4%) 0.94 (0.85–1.04)
Nifedipine 1,999 303 (15.2%) 0.97 (0.84–1.12)
Diltiazem 3,320 444 (13.4%) 0.89 (0.79–1.01)
Verapamil 350 54 (15.4%) 1.04 (0.79–1.39)
Combination 174 39 (22.4%) 1.28 (0.91–1.80)
*Adjustment made by the Cox proportional hazard model for age, gender
and current and past smoking, diabetes mellitus, past myocardial infarction,
angina pectoris, functional class, hypertension, peripheral vascular disease and
chronic obstructive pulmonary disease. Abbreviations as in Table 2.
Table 4. Adjusted Relative Risk Estimates for Cancer-Related






CCB nonusers 5,543 75 (1.4%) 1
CCB users
Total 5,611 83 (1.5%) 1.03 (0.75–1.41)
Nifedipine 1,913 38 (2.0%) 1.34 (0.90–1.98)
Diltiazem 3,193 35 (1.1%) 0.78 (0.52–1.17)
Verapamil 336 6 (1.8%) 1.22 (0.53–2.81)
Combination 169 4 (2.4%) 1.72 (0.63–4.70)
*Patients with known cancer at screening visit were excluded. †Adjusted for
age, gender and smoking. Abbreviations as in Table 2.
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Comparison with other studies. In a recent investigation of
5,052 EPESE patients, Pahor et al. (2) reported that CCB
users exhibited a 1.42-fold increase in cancer incidence over
nonusers. CCB users differed to a great extent from those who
were not using them. Two dramatic differences were the
prevalence of CHD in 71% and heart failure in 29% among the
users compared with only 22% and 10%, respectively, among
the nonusers. Disease severity was not recorded. There was
also a sizable excess of diabetes prevalence among users of
CCBs. Concomitant use of nitrates, diuretic drugs, digoxin,
beta-blockade and ACE inhibitors among users, in correspon-
dence to the large excess of CHD, was also highly increased.
Physical disability was recorded for 63% of CCB users and
45% of nonusers. Multivariate analysis, adjusted for age,
gender, ethnicity, current smoking and drinking, the presence
of diagnosed heart failure and number of hospital admissions,
increased the estimated relative cancer incidence risk to 1.72.
Pahor et al. (2) failed to adjust for lifetime smoking and
drinking habits, two potential harbingers of cancer in these
elderly patients. These and other vital exposures over time may
well have been related to both CHD (hence, a higher likeli-
hood of CCB prescription) and subsequent cancer. Our cohort
included only patients with CHD who were considerably
younger than the subjects in the EPESE cohort. Our analysis,
including an adjustment encompassing past smoking, failed to
indict CCBs as increasing the risk of cancer incidence and
cancer-related mortality. In the study by Jick et al. (7), after
adjustment for smoking body mass index, change in medication
and duration and dose of CCBs, the absence of a duration
effect renders a causal explanation of a small association of
cancer risk with CCBs unlikely.
A significant point in assessing the safety of a drug by
comparing the statistics of subsequent events or death is the
“bias by indication,” in that doctors prescribe medication to a
patient on the basis of a decision that is not fully documented
in terms of all clinical consideration and pertinent variables.
Users and nonusers of a certain drug are therefore certain to
differ in many important ways. Attempts to compare their fate
by observation serves as a preliminary substitute to the appro-
priate examination of safety through randomized trials and
should be conducted and interpreted with the utmost caution.
Thus, the postulated hypothesis that inhibition of apoptosis by
CCBs (8) may promote cancer remains hypothetical and
speculative.
Study limitations. There are several potential limitations
of cohort studies. Similar to other studies, we conducted an
observational analysis in groups with different characteristics
and adjusted statistically for the differences, rather than judg-
ing experimentally an effect of medication on morbidity and
mortality (9) in a randomized clinical trial. In the present
study, we relied on a single report of therapy for each patient
made available to us during a screening examination. Therapy
may undergo several changes within a given follow-up period
and is a shortcoming of most observational studies, including
recent ones (1,2,10). Although we do not know who of the
actual patients in the cohort presently analyzed discontinued
CCBs or, conversely, was not taking CCBs initially but started
therapy during follow-up, we have, unlike other studies, an
indirect estimate for the extent of such changes. These esti-
mates were derived from the experience of the patients
participating in the clinical trial (BIP) proper, not included in
this cohort. Among 1,593 patients taking CCBs at the begin-
ning of the trial, 83.9% of those alive and evaluated 1 year later
(n 5 1,544) were still taking CCBs. This proportion dropped to
70.9% after 4 years. Conversely, in 1,529 patients not using
CCBs at baseline, 8.8% of those surviving and evaluated 1 year
later (n 5 1,474) started CCB therapy within the first year,
increasing to 18.2% within 4 years.
The wide confidence intervals, resulting from the limited
number of cancer incidence cases and cancer deaths, provides
(given the low rates) no grounds for labeling CCBs as promot-
ing cancer in patients with CHD. We are proceeding to follow
up this cohort to obtain more stable estimates of the risk of
cancer incidence and mortality and to learn more about
long-term associations.
These limitations notwithstanding, the results were derived
from a large number of patients with chronic CHD, after
adjusting for comorbidity, disease severity and past smoking
habits, potentially related to the likelihood of cancer. Thus, the
analysis is of significance in assessing the safety of CCB use in
patients with CHD until decisive results from ongoing random-
ized clinical trials are available.
Conclusions. Patients with CHD treated with CCBs exhib-
ited a similar risk for the incidence of cancer, overall mortality
and cancer-related mortality as did nonusers of CCBs. Our
analysis provides a certain assurance that CCB use in middle-
aged and elderly patients with CHD is not associated with a
meaningful difference in mortality and cancer incidence.
Appendix
Participating Centers and Investigators for the
Benzafibrate Infarction Prevention Study Group
Assaf Harofe Hospital, Zrifin: Zwi Schlesinger, MD, Aharon Friden-
sohn, MD. Barzilai Medical Center, Ashkelon: Leonardo Reisin, MD,
Jamal Jafari, MD. Beilinson Medical Center, Petach Tikva: Samuel
Sclarovsky, MD, Yaakov Friedman, MD, Bruno Ostfeld, MD. Bnei-
Zion Hospital, Haifa: Edward Abinader, MD, Shmuel Rochfleish, MD.
Carmel Hospital, Haifa: Abraham Palant, MD, Hanan Schneider, MD.
Central HaEmek Hospital, Afula: Tiberio Rosenfeld, MD, Suleiman
Khalid, MD. Edith Wolfson Medical Center, Holon: Yehezkiel Kishon,
MD Rene Rotzak, MD. Hasharon Hospital, Petach-Tikva: Izhar Za-
havi, MD, Janash Vitrai, MD. Hillel Yaffe Hospital, Hadera: Benyamin
Pelled, MD, Joseph Pardu, MD. Tel Aviv Medical Center, Tel-Aviv:
Shlomo Laniado, MD, Libi Sherf, MD, Shimon Braun, MD, Yemima
Eschar, MD. Kaplan Hospital, Rehovot: Avraham Caspi, MD, Alex-
ander Arditi, MD, Shulamit Botwin, MD. Meir Hospital, Sapir Medical
Center, Kfar Saba: Daniel David, MD, Daniel Weisnenberg, MD;
Naharia Hospital, Naharia: Nathan Roguin, MD, Alicia Glusman, MD;
Rambam Medical Center, Haifa: Walter Markiewicz, MD, Diav Motlak,
MD; Rivka Ziv Hospital, Tzfad: Alon Marmour, MD, Michael Flich,
MD; Shaare Zedek Medical Center, Jerusalem: Monty Zion, MD,
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Jonathan Balkin, MD; Sheba Medical Center Heart Institute, Tel
Hashomer: Babeth Rabinowitz, MD, Eddy Barasch, MD; Soroka
Medical Center, Be’er Sheba: Natalio Kristal, MD, Noa Liel, MD.
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